Ferry Ossendorp - Concepedia

Author

Ferry Ossendorp

Also Known As

F A Ossendorp, F OSSENDORP, F Ossendorp, F. A. Ossendorp, F. OSSENDORP, F. Ossendorp, FA Ossendorp, FERRY A. OSSENDORP, Ferry A Ossendorp, Ferry A. Ossendorp

357

Publications

17.9K

Citations

H-Index

127

Concepts

All Affiliations

Leiden University Medical Center Leiden University The Netherlands Cancer Institute ISA Pharmaceuticals (Netherlands)Oncode Institute

About

Ferry Ossendorp is an author at Leiden University Medical Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	45	89	7.8K
2	Allergy	18	21	1.8K
3	Engineering	10	10	653
4	Natural Sciences	8	8	578
5	Health Sciences	3	3	71

Ferry Ossendorp

174

Publications

13.2K

Citations

H-Index

Page 1

	Year	Citations
Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors Ferry Ossendorp, Erica Mengedé, Marcel Camps, The Journal of Experimental Medicine Cytotoxic T LymphocytesClass IiT-regulatory CellImmunologyPathology	1998	600
Decreased tumor surveillance in perforin-deficient mice. Maries van den Broek, David Kägi, Ferry Ossendorp, The Journal of Experimental Medicine ImmunologyNk CellsPathologyImmunologic MechanismImmunotherapy	1996	483
MHC II in Dendritic Cells is Targeted to Lysosomes or T Cell‐Induced Exosomes Via Distinct Multivesicular Body Pathways Sonja I. Buschow, Esther N. M. Nolte‐‘t Hoen, Guillaume van Niel, Traffic Adaptive Immune SystemImmunologyImmunologic MechanismAntigen ProcessingExtracellular Microvesicles	2009	409
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy Marieke F. Fransen, Mark J.A. Schoonderwoerd, Philipp Knopf, JCI Insight Lymphoid NeoplasiaTumor ImmunologyCancer ImmunosurveillanceCheckpoint TherapyMedicine	2018	370
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy Maud Mayoux, Andreas Roller, Vesna Pulko, Science Translational Medicine Dc Gene SignatureTumor ImmunologyCancer ImmunosurveillancePd-l1 BlockadeMedicine	2020	361
CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope Ania Skowera, Richard J. Ellis, Rubén Varela‐Calviño, Journal of Clinical Investigation	2008	360
Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells Monique J. Kleijmeer, Georg Ramm, Danita H. Schuurhuis, The Journal of Cell Biology ImmunologyMolecular BiologyAntigen ProcessingExtracellular MicrovesiclesCytoskeleton	2001	282
Autoreactive CD8 T cells associated with β cell destruction in type 1 diabetes Gabriëlle G.M. Pinkse, Odette H. M. Tysma, Cees A. M. Bergen, Proceedings of the National Academy of Sciences	2005	277
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses Rodney Alexander Rosalia, Luis J. Cruz, Suzanne van Duikeren, Biomaterials VaccinationNanomedicineCross-protectionTumor ImmunologyImmunology	2014	265
Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis Jan H. Kessler, N. J. C. M. Beekman, Sandra A. Bres-Vloemans, The Journal of Experimental Medicine HistocompatibilityHla ImmunogeneticsImmunologyImmune RegulationImmunodominance	2001	263

Page 1